Confirm the intended product
A shared active ingredient can appear across products with different labeling, indications, strengths and market status.
Active ingredient comparison
Pomalidomide appears in 8 brand or manufacturer-labeled product profiles in the US Med Access catalog, covering 74 dated package references. European estimated medicine cost references currently range from €3,147.53 – €10,736.33, while captured comparable U.S. cash references range from $12,628.84 – $24,476.71. A shared ingredient does not make different products, strengths, dosage forms or packages interchangeable.
Multi-product ingredient index
Open the exact profile before comparing figures. Brand, manufacturer, authorization, dosage form, strength and package quantity can differ even when the named active ingredient is the same.
| Brand or product | Category | Packages | European reference | Comparable U.S. cash | Profile |
|---|---|---|---|---|---|
| IMNOVIDBristol-Myers Squibb GmbH & Co. KGaA | Specialty Care | 9 | €6,816.53 to €10,736.33 | $12,628.84 | Open profile → |
| POMADELTAD Pharma GmbH | Specialty Care | 4 | €3,693.69 to €4,019.29 | $18,943.26 | Open profile → |
| PomalidomidMultiple EU-listed suppliers | Oncology | 30 | €3,585.66 to €6,934.44 | Not listed | Open profile → |
| POMALIDOMID 123 Acurae Pharma123 Acurae Pharma GmbH | Specialty Care | 4 | €3,693.69 to €4,019.29 | $18,943.26 | Open profile → |
| POMALIDOMID AccordAccord Healthcare GmbH | Specialty Care | 8 | €3,746.66 to €6,934.44 | $16,317.81 | Open profile → |
| POMALIDOMID Tevaratiopharm GmbH | Specialty Care | 4 | €3,641.95 to €3,986.95 | $18,943.26 | Open profile → |
| POMALIDOMID ViatrisViatris Healthcare GmbH | Specialty Care | 8 | €3,642.01 to €5,757.88 | $12,628.84 | Open profile → |
| POMALIDOMID ZentivaZentiva Pharma GmbH | Specialty Care | 7 | €3,147.53 to €3,873.16 | $12,628.84 | Open profile → |
How to use this page
Open each product profile and match the intended brand, manufacturer, strength, dosage form and package quantity. Only compare cost references after the products are meaningfully comparable.
A shared active ingredient can appear across products with different labeling, indications, strengths and market status.
Compare equivalent quantities and retain the original package description beside any unit-level calculation.
Price, availability, source status, exchange rates and route requirements can change after publication.
Product-specific review
Share the intended brand, strength, dosage form, quantity, destination and organization type. No substitution, supply or import outcome is guaranteed.